Secondary Schizophrenia (48 page)

for psychosis. Neuropsycho-

of self-reported psychotic

2003.
33
:1407–14.

pharmacology, 2004.
29
:1558–72.

symptoms in the British

5. Brady K. T., Lydiard R. B.,

14. D’Souza D. C., Abi-Saab W. M.,

population. Br J Psychiatry, 2004.

Malcolm R., Ballenger J. C.

Madonick S.,
et al.
Delta-9-

185
:298–305.

Cocaine-induced psychosis. J Clin

tetrahydrocannabinol effects in

24. Degenhardt L., Hall W. The

Psychiatry, 1991.
52
:509–12.

schizophrenia: implications for

association between psychosis and

6. Cubells J. F., Feinn R., Pearson D.,

cognition, psychosis, and

problematical drug use among

et al.
Rating the severity and

addiction. Biol Psychiatry, 2005.

Australian adults: findings from

character of transient

57
:594–608.

the National Survey of Mental

cocaine-induced delusions and

15. Bakker C. B., Amini F. B.

Health and Well-Being. Psychol

hallucinations with a new

Observations on the

Med, 2001.
31
:659–68.

instrument, the Scale for

psychotomimetic effects of Sernyl.

25. Skosnik P. D., Spatz-Glenn L.,

Assessment of Positive Symptoms

Compr Psychiatry, 1961.
2
:
Park S. Cannabis use is associated

for Cocaine-Induced Psychosis

269–80.

with schizotypy and attentional

(SAPS-CIP). Drug Alcohol

16. Breier A., Malhotra A. K., Pinals

disinhibition. Schizophr Res, 2001.

Depend, 2005.
80
:23–33.

D. A., Weisenfeld N. I., Pickar D.

48
:83–92.

7. Curran C., Byrappa N., McBride

Association of ketamine-induced

26. Verdoux H., Sorbara F., Gindre

A. Stimulant psychosis: systematic

psychosis with focal activation of

C., Swendsen J. D., van Os J.

review. Br J Psychiatry, 2004.

the prefrontal cortex in healthy

Cannabis use and dimensions of

185
:196–204.

volunteers. Am J Psychiatry, 1997.

psychosis in a nonclinical

154
:805–11.

8. Angrist B. M., Gershon S. The

population of female subjects.

phenomenology of

17. Strauss J. S. Hallucinations and

Schizophr Res, 2002.
59
:77–84.

experimentally induced

delusions as points on continua

27. Verdoux H., Gindre C., Sorbara

amphetamine psychosis –

function. Rating scale evidence.

F., Tournier M., Swendsen J. D.

preliminary observations. Biol

Arch Gen Psychiatry, 1969.

Effects of cannabis and psychosis

Psychiatry, 1970.
2
:95–107.

21
:581–6.

vulnerability in daily life: an

9. Cami J., Farre M., Mas M.,

18. Claridge G. Single indicator of

experience sampling test study.

et al.
Human pharmacology of 3,4-

risk for schizophrenia: probable

Psychol Med, 2003.
33
:23–32.

methylenedioxymethamphetamine

fact or likely myth? Schizophr Bull,

28. Degenhardt L., Hall W. The

(“ecstasy”): psychomotor

1994.
20
:151–68.

association between psychosis and

performance and subjective

19. Coleman M. J., Levy D. L.,

problematical drug use among

effects. J Clin Psychopharmacol,

Lenzenweger M. F., Holzman P. S.

Australian adults: findings from

123

2000.
20
:455–66.

Thought disorder, perceptual

the National Survey of Mental

Organic Syndromes of Schizophrenia – Section 3

Health and Well-Being. Psychol

schizophrenia? Nervenarzt, 1996.

Am J Psychiatry, 1970.
126
:
Med, 2001.
31
:659–68.

67
:36–45.

983–7.

29. Skosnik P. D., Spatz-Glenn L.,

39. Floyd A. G., Boutros N. N., Struve

47. Caton C. L., Drake R. E., Hasin D.

Park S. Cannabis use is associated

F. A., Wolf E., Oliwa G. M. Risk

S.,
et al.
Differences between

with schizotypy and attentional

factors for experiencing psychosis

early-phase primary psychotic

disinhibition. Schizophr Res, 2001.

during cocaine use: a preliminary

disorders with concurrent

48
:83–92.

report. J Psychiatr Res, 2006.

substance use and

30. Verdoux H., Sorbara F., Gindre

40
:178–82.

substance-induced psychoses.

C., Swendsen J. D., van Os J.

Arch Gen Psychiatry, 2005.

40. Dalmau A., Bergman B., Brismar

Cannabis use and dimensions of

62
:137–45.

B. Psychotic disorders among

psychosis in a nonclinical

inpatients with abuse of cannabis,

48. Caton C. L., Hasin D. S., Shrout P.

population of female subjects.

amphetamine and opiates. Do

E.,
et al.
Stability of early-phase
Schizophr Res, 2002.
59
:77–84.

dopaminergic stimulants facilitate

primary psychotic disorders with

31. Verdoux H., Gindre C., Sorbara

psychiatric illness? Eur Psychiatry,

concurrent substance use and

F., Tournier M., Swendsen J. D.

1999.
14
:366–71.

substance-induced psychosis. Br J

Effects of cannabis and psychosis

Psychiatry, 2007.
190
:105–11.

41. Margolese H. C., Malchy L.,

vulnerability in daily life: an

Negrete J. C., Tempier R., Gill K.

49. Tsuang M. T., Simpson J. C.,

experience sampling test study.

Drug and alcohol use among

Kronfol Z. Subtypes of drug abuse

Psychol Med, 2003.
33
:23–32.

patients with schizophrenia and

with psychosis. Demographic

32. van Os J., Bak M., Hanssen M.,

related psychoses: levels and

characteristics, clinical features,

et al.
Cannabis use and psychosis:
consequences. Schizophr Res,

and family history. Arch Gen

a longitudinal population-based

2004.
67
:157–66.

Psychiatry, 1982.
39
:141–47.

study. Am J Epidemiol, 2002.

42. Farrell M., Boys A., Bebbington P.,

50. Kendler K. S. A twin study of

156
:319–27.

et al.
Psychosis and drug

individuals with both

33. Ferdinand R. F., Sondeijker F.,

dependence: results from a

schizophrenia and alcoholism.

Van Der Ende J.,
et al.
Cannabis

national survey of prisoners.

Br J Psychiatry, 1985.
147
:48–
use predicts future psychotic

Br J Psychiatry, 2002.
181
:
53.

symptoms, and vice versa.

393–8.

51. Glass I. B. Alcoholic hallucinosis:

Addiction, 2005.
100
:612–18.

43. Smith M. J., Thirthalli J., Abdalla

a psychiatric enigma–2.

34. Henquet C., Krabbendam L.,

A. B., Murray R. M., Cottler L. B.

Followup studies. Br J Addict,

Spauwen J.,
et al.
Prospective

Prevalence of psychotic symptoms

1989.
84
:151–64.

cohort study of cannabis use,

in substance users: a comparison

52. Tsuang J. W., Irwin M. R., Smith

predisposition for psychosis, and

across substances. Comprehensive

T. L., Schuckit M. A.

psychotic symptoms in young

Psychiatry, 2009.
50
:245–50.

Characteristics of men with

people. Br Med J, 2005.
330
:11.

44. van Os J., Hanssen M., Bijl R. V.,

alcoholic hallucinosis. Addiction,

35. Arseneault L., Cannon M.,

Vollebergh W. Prevalence of

1994.
89
:73–8.

Poulton R.,
et al.
Cannabis use in
psychotic disorder and

53. Kalayasiri R., Kranzler H. R.,

adolescence and risk for adult

community level of psychotic

Weiss R.,
et al.
Risk factors for
psychosis: longitudinal

symptoms: an urban-rural

cocaine-induced paranoia in

prospective study. Br Med J, 2002.

comparison. Arch Gen Psychiatry,

cocaine-dependent sibling pairs.

325
:1212–3.

2001.
58
:663–8.

Drug Alcohol Depend, 2006.

36. Fergusson D. M., Horwood L. J.,

45. Cannon M., Caspi A., Moffitt T.

84
:77–84.

Ridder E. M. Tests of causal

E.,
et al.
Evidence for early-

54. Satel S. L., Southwick S. M.,

linkages between cannabis use

childhood, pan-developmental

Gawin F. H. Clinical features of

and psychotic symptoms.

impairment specific to

cocaine-induced paranoia. Am J

Addiction, 2005.
100
:354–66.

schizophreniform disorder:

Psychiatry, 1991.
148
:495–98.

37. Olfson M., Lewis-Fernandez R.,

results from a longitudinal birth

55. Sato M., Chen C. C., Akiyama K.,

Weissman M. M.,
et al.
Psychotic

cohort. Arch Gen Psychiatry, 2002.

Otsuki S. Acute exacerbation of

symptoms in an urban general

59
:449–56.

paranoid psychotic state after

medicine practice. Am J

46. Robins E., Guze S. B.

long-term abstinence in patients

Psychiatry, 2002.
159
:1412–19.

Establishment of diagnostic

with previous methamphetamine

38. Hambrecht M., Hafner H. Do

validity in psychiatric illness: its

psychosis. Biol Psychiatry, 1983.

124

alcohol or drug abuse induce

application to schizophrenia.

18
:429–40.

Chapter 8 – Substance-induced psychosis: an overview

56. Bartlett E., Hallin A., Chapman B.,

without psychosis. Am J Med

dysregulation. Science, 1997.

Angrist B. Selective sensitization

Genet B Neuropsychiatr Genet,

278
:52–8.

to the psychosis-inducing effects

2005.
136
:87–91.

74. Epping-Jordan M. P., Markou A.,

of cocaine: a possible marker for

64. McGuire P. K., Jones P., Harvey I.,

Koob G. F. The dopamine D-1

addiction relapse vulnerability?

et al.
Morbid risk of schizophrenia
receptor antagonist SCH 23390

Neuropsychopharmacology, 1997.

for relatives of patients with

injected into the dorsolateral bed

16
:77–82.

cannabis-associated psychosis.

nucleus of the stria terminalis

57. Reid M. S., Ciplet D., O’Leary S.,

Schizophr Res, 1995.
15
:277–81.

decreased cocaine reinforcement

et al.
Sensitization to the

in the rat. Brain Res, 1998.

65. Satel S. L., Edell W. S. Cocaine-

psychosis-inducing effects of

784
:105–15.

induced paranoia and psychosis

cocaine compared with measures

proneness. Am J Psychiatry, 1991.

75. Self D. W., Stein L. The D1

of cocaine craving and cue

148
:1708–11.

agonists SKF 82958 and SKF

reactivity. Am J Addict, 2004.

77434 are self-administered by